Asia Pacific clinical trials market will grow by 8.4% annually with a total addressable market cap of $97,110.8 million over 2023-2031, driven by the increasing number of clinical trials and increase in demand for novel therapies, rising prevalence on chronic diseases such as cancer and diabetes, the outbreak of tropical and infectious diseases such as COVID-19, and the increase in government initiatives and R&D investments.
Highlighted with 99 tables and 79 figures, this 186-page report "Asia Pacific Clinical Trials Market 2022-2031 by Product Category (Drugs, Devices, Procedures), Phase (I, II, III, IV), Design (Interventional, Observational, Expanded Access), Service Type (Site Identification, Lab Services, Supply & Logistic, Decentralized Services), Indication (Oncology, Infectious Diseases, Cardiology, Obesity, Diabetes, Neurology), End User, and Country: Trend Forecast and Growth Opportunity" is based on a comprehensive research of the entire Asia Pacific clinical trials market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2022 and provides forecast from 2023 till 2031 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific clinical trials market in every aspect of the classification from perspectives of Product Category, Phase, Design, Service Type, Indication, End User, and Country.
Based on Product Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Trials of Drugs
o Small Molecule Drugs
o Vaccines
o Cell & Gene Therapy
o Other Drugs
• Trials of Devices
• Trials of Procedures
Based on Phase, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Phase I
• Phase II
• Phase III
• Phase IV
By Design, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Interventional Studies
o Randomized Control Trial
o Adaptive Clinical Trial
o Non-randomized Control Trial
• Observational Studies
o Cohort Study
o Case Control Study
o Cross Sectional Study
o Ecological Study
• Expanded Access Trials
By Service Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Protocol Designing
• Site Identification
• Patient Recruitment
• Laboratory Services
• Bioanalytical Testing Services
• Clinical Trial Data Management Services
• Clinical Trial Supply & Logistic Services
• Decentralized Clinical Trial Services
• Medical Device Testing Services
• Other Clinical Trial Services
By Indication, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Oncology
• Infectious Diseases
• Cardiology
• Obesity
• Diabetes
• Neurology
• Immunology
• Pain Management
• Other Indications
By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section.
• Pharmaceutical and Biotechnological Companies
• Clinical Research Organizations
• Clinical Testing Laboratories
• Other End Users
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2031. The breakdown of each national market by Phase, Design, and Indication over the forecast years are also included.
The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Accell Clinical Research LLC
Charles River Laboratories
ClinDatrix Inc
Clinipace
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
ICON PLC
IQVIA Holdings, Inc.
Laboratory Corporation of America (Covance Inc.)
Novo Nordisk AS
PAREXEL International Corporation
Pfizer Inc.
Pharmaceutical Product Development LLC
PhlexAsia Pacific
PRA Health Sciences
Sanofi SA
SGS SA (SGS Life Sciences)
Syneos Health Inc.
Wuxi AppTec Inc.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 11
1.1 Industry Definition and Research Scope 11
1.1.1 Industry Definition 11
1.1.2 Research Scope 12
1.2 Research Methodology 15
1.2.1 Overview of Market Research Methodology 15
1.2.2 Market Assumption 16
1.2.3 Secondary Data 16
1.2.4 Primary Data 16
1.2.5 Data Filtration and Model Design 17
1.2.6 Market Size/Share Estimation 18
1.2.7 Research Limitations 19
1.3 Executive Summary 20
2 Market Overview and Dynamics 23
2.1 Market Size and Forecast 23
2.1.1 Impact of COVID-19 on World Economy 25
2.1.2 Impact of COVID-19 on the Market 28
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery 30
2.2 Major Growth Drivers 34
2.3 Market Restraints and Challenges 41
2.4 Emerging Opportunities and Market Trends 44
2.5 Porter's Fiver Forces Analysis 48
3 Segmentation of Asia Pacific Market by Product Category 52
3.1 Market Overview by Product Category 52
3.2 Trials of Drugs 54
3.2.1 Small Molecule Drugs 55
3.2.2 Vaccines 56
3.2.3 Cell & Gene Therapy 57
3.2.4 Other Drugs 58
3.3 Trials of Devices 59
3.4 Trials of Procedures 60
4 Segmentation of Asia Pacific Market by Phase 61
4.1 Market Overview by Phase 61
4.2 Phase I 63
4.3 Phase II 64
4.4 Phase III 65
4.5 Phase IV 66
5 Segmentation of Asia Pacific Market by Design 67
5.1 Market Overview by Design 67
5.2 Interventional Studies 69
5.2.1 Randomized Control Trial 71
5.2.2 Adaptive Clinical Trial 72
5.2.3 Non-randomized Control Trial 73
5.3 Observational Studies 74
5.3.1 Cohort Study 76
5.3.2 Case Control Study 77
5.3.3 Cross Sectional Study 78
5.3.4 Ecological Study 79
5.4 Expanded Access Trials 80
6 Segmentation of Asia Pacific Market by Service Type 81
6.1 Market Overview by Service Type 81
6.2 Protocol Designing 83
6.3 Site Identification 84
6.4 Patient Recruitment 85
6.5 Laboratory Services 86
6.6 Bioanalytical Testing Services 87
6.7 Clinical Trial Data Management Services 88
6.8 Clinical Trial Supply & Logistic Services 89
6.9 Decentralized Clinical Trial Services 90
6.10 Medical Device Testing Services 91
6.11 Other Clinical Trial Services 92
7 Segmentation of Asia Pacific Market by Indication 93
7.1 Market Overview by Indication 93
7.2 Oncology 95
7.3 Infectious Diseases 96
7.4 Cardiology 97
7.5 Obesity 98
7.6 Diabetes 99
7.7 Neurology 100
7.8 Immunology 101
7.9 Pain Management 102
7.10 Other Indications 103
8 Segmentation of Asia Pacific Market by End User 104
8.1 Market Overview by End User 104
8.2 Pharmaceutical and Biotechnological Companies 106
8.3 Clinical Research Organizations 107
8.4 Clinical Testing Laboratories 108
8.5 Other End Users 109
9 Asia-Pacific Market 2021-2031 by Country 110
9.1 Overview of Asia-Pacific Market 110
9.2 Japan 113
9.3 China 116
9.4 Australia 118
9.5 India 120
9.6 South Korea 122
9.7 Rest of APAC Region 124
10 Competitive Landscape 126
10.1 Overview of Key Vendors 126
10.2 New Product Launch, Partnership, Investment, and M&A 130
10.3 Company Profiles 131
Accell Clinical Research LLC 131
Charles River Laboratories 133
ClinDatrix Inc 136
Clinipace 137
Eli Lilly and Company 139
F. Hoffmann-La Roche Ltd. 142
ICON PLC 145
IQVIA Holdings, Inc. 148
Laboratory Corporation of America (Covance Inc.) 152
Novo Nordisk AS 156
PAREXEL International Corporation 159
Pfizer Inc. 163
Pharmaceutical Product Development LLC 168
Phlexglobal 171
PRA Health Sciences 173
Sanofi SA 175
SGS SA (SGS Life Sciences) 178
Syneos Health Inc. 181
Wuxi AppTec Inc. 184
RELATED REPORTS 186
The Clinical Trial Simulation Tools Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, man...
The Cloud Computing in Clinical Trials Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, ...
Market Overview
The Asia Pacific Vanadium Market is poised for substantial growth from 2024 to 2034, driven by increasing demand across various industries and technological advancements in vanadium production. The market is projected to reach USD XX.XX billion by 2034, growing at a comp...
Market Overview
The Asia Pacific Vascular Closure Devices Market is anticipated to experience substantial growth from 2024 to 2034. The market's expansion is fueled by advancements in vascular closure technologies, increasing prevalence of cardiovascular diseases, and the growing adopti...
Market Overview
The Asia Pacific Nuclear Medicine Market is poised for significant growth from 2024 to 2034, driven by advancements in nuclear imaging technologies, increased application in various medical fields, and rising healthcare investments across the region. The market is expect...
Market Overview
The Asia Pacific Anti-Pollution Mask Market is set to experience substantial growth from 2024 to 2034. Starting with a market valuation of USD XX.XX billion in 2024, it is projected to reach USD XX.XX billion by 2034, reflecting a significant compound annual growth rate ...
Market Overview
The Asia Pacific Ethnic Wear Market is anticipated to experience robust growth from 2024 to 2034. Starting with a market valuation of USD XX.XX billion in 2024, it is projected to surge to USD XX.XX billion by 2034, reflecting a strong compound annual growth rate (CAGR) ...
Market Overview
The Asia Pacific FinTech Investment Market is poised for significant expansion from 2024 to 2034. With an initial valuation of USD XX.XX billion in 2024, the market is forecasted to reach USD XX.XX billion by 2034, reflecting a robust compound annual growth rate (CAGR) o...
Market Overview
The Asia Pacific Airport Asset Tracking Market is anticipated to witness significant growth from 2024 to 2034, propelled by the increasing need for efficient asset management and operational visibility in the aviation sector. The market is projected to reach USD XX.XX bi...
Market Overview
The Asia Pacific Sustainable Aviation Fuel Market is positioned for substantial growth from 2024 to 2034, driven by escalating environmental regulations, increasing corporate sustainability initiatives, and a growing emphasis on reducing aviation carbon emissions. The ma...